A universal carrier test for the long tail of Mendelian disease.
Level 5 - mechanism / opinion, no new human data
Laboratory assay development and technical validation study (bench research without prospective clinical outcome trial).
PubMed 20729146 · doi:10.1016/j.rbmo.2010.05.012
What was done
The authors developed and tested a saliva-based multiplex universal carrier screening assay covering more than 100 Mendelian diseases across major population groups. The assay was analytically validated using a median of 147 positive and 525 negative samples per variant and compared against standard blood-based single-gene carrier tests.
What was found
The assay was validated across a panel of over 100 Mendelian disorders with a median of 147 positive and 525 negative samples per variant, with performance described as comparing favorably to standard single-gene tests. Exact quantitative accuracy metrics (e.g., sensitivity, specificity, concordance rates, failure rates) are not reported in the abstract.
Why it matters
The study outlines a scalable multiplex genetic testing method to expand preconception carrier screening beyond traditional single-ethnicity target panels to broader populations using non-invasive saliva sampling.
Limits
The abstract provides no numerical data on diagnostic sensitivity, specificity, positive predictive value, or error rates. Total unique human subjects tested, composition of the variant panel, and real-world clinical utility or psychological/behavioral outcomes in a prospective population screening cohort are not reported.
Cited by
- supports Preconception genetic screening and mate-selection programs in specific populations have virtually eliminated certain severe inherited genetic diseases.